Eli Lilly and Company (NEO:ZLLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.56T +49.9% |
| Revenue (ttm) | 113.13B +49.6% |
| Net Income | 37.93B +93.6% |
| EPS | 42.30 +94.8% |
| Shares Out | n/a |
| PE Ratio | 41.78 |
| Forward PE | 32.56 |
| Dividend | 0.05 (0.39%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 92 |
| Open | 13.22 |
| Previous Close | 13.28 |
| Day's Range | 13.22 - 13.22 |
| 52-Week Range | 9.09 - 13.45 |
| Beta | 0.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
METiS TechBio enters up to $1.1B collaboration with Eli Lilly
METiS TechBio announced a strategic collaboration with Eli Lilly (LLY) and Company focused on the research and discovery of novel lipid nanoparticle-based delivery solutions designed to enable tissue-...
Eli Lilly price target raised to $1,397 from $1,341 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,397 from $1,341 and keeps a Buy rating on the shares. The firm’s Q3 physician obesity survey adds validation…
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech
Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies...
Eli Lilly announces SHINE-2 study of Omvoh meets primary endpoint
Eli Lilly (LLY) announced late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis, or…
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than...
Eli Lilly presents new data from its oncology portfolio at ESMO
Eli Lilly (LLY) and Company announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology, ESMO, Congress, taking place October 23-27…
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
First Phase 1 data for sofetabart mipitecan, Lilly's investigational FR α -targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation Updated first-line data for o...
EMA adopts positive opinion on Eli Lilly’s Foundayo, recommending approval
On October 15, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Foundayo, intended for th...
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that...
Eli Lilly’s Omvoh shows efficacy in ulcerative colitis and Crohn’s disease
Eli Lilly (LLY) reported new data analyses showing patients with moderately to severely active ulcerative colitis, or UC, and Crohn’s disease treated with Omvoh achieved multiple treatment goals simul...
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endosco...
Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab
Adlai Nortye (ANL) announced clinical trial collaboration and supply agreements, or CTCSAs, with Eli Lilly (LLY) and Merck KGaA (MKGAF) for the anti-EGFR antibody cetuximab. These agreements will supp...
H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly
H.C. Wainwright reiterates a Buy rating on Prelude Therapeutics (PRLD) with an $8 price target after the company announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY).
Prelude enters clinical trial collaboration, supply agreement with Eli Lilly
Prelude Therapeutics (PRLD) announced a clinical trial collaboration and supply agreement with Eli Lilly (LLY) for supply of its CDK4/6 kinase inhibitor, abemaciclib and its oral estrogen receptor ant...
Eli Lilly (LLY) Stock: Why Taking Profits Could Make Sense Ahead of 2027
Shares of drug maker Eli Lilly ($LLY) have modestly underperformed the S&P 500 ($SPY) in 2026, with large-cap U.S. stock returns increasingly driven by AI beneficiaries such as Micron ($MU)…
Eli Lilly announces new TOGETHER-PsO trial data
Eli Lilly (LLY) announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared with Taltz alone in adults with moderate-to-s...
Eli Lilly price target lowered to $1,341 from $1,344 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Eli Lilly (LLY) to $1,341 from $1,344 and keeps a Buy rating on the shares as part of the firm’s…
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct....
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Eli Lilly price target raised to $1,440 from $1,410 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Eli Lilly (LLY) to $1,440 from $1,410 and keeps an Overweight rating on the shares. Eli Lilly faces a…
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines
The World Health Organization (WHO) issued its first-ever guidelines on childhood and adolescent obesity on Wednesday. The guidelines discourage weight-loss drugs for children under 10 years. Instead,...
Eli Lilly price target raised to $1,430 from $1,419 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,430 from $1,419 and keeps an Overweight rating on the shares. The firm adjusted its models for its…
Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug
Cancer treatments are a growth area for the drug company,…